SPARK NS allocates up to USD 18m to 9 academic projects in autism and Parkinson’s

SPARK NS, an independent nonprofit translational research organization headquartered in Menlo Park, California, has selected nine academic projects and principal investigators to receive up to USD 18 million in milestone-based funding through its Translational Research Program. The projects focus on therapeutics for autism and Parkinson’s disease, based in academic and nonprofit research institutions in the US, UK, and Europe. Each project is eligible for up to USD 2 million over a two-year period to support the advancement of laboratory-stage discoveries in autism and Parkinson’s disease toward clinical development.

Founded in 2023, SPARK NS focuses on bridging the gap between academic drug discovery and clinical-stage therapeutic development in neurological and neurodevelopmental disorders. The organization distributes non-dilutive, milestone-based funding rather than venture capital investment. Work performed by vetted contract research organizations or academic facilities may be paid for directly by SPARK NS.

The nine new projects bring the total number of active programs in the SPARK NS Translational Research Program to 22, collectively eligible for up to USD 44 million in funding. This includes eight projects selected in 2025 and five from the 2024 cohort, with details of all 22 principal investigators involved available here.

Funded Parkinson’s disease projects include approaches targeting neuroinflammation, lipid metabolism, enhancement of the autophagic-lysosomal pathway, and human genetics-driven disease modification.

In autism, selected programs include those targeting SHANK3-related autism (Phelan-McDermid syndrome), RNA-targeted small molecule therapeutics, modulation of GABAergic signaling, and a gene therapy targeting CTNNB1-linked autism.

The only confirmed active clinical trial associated with the SPARK NS network is D-SPARK, a Phase II placebo-controlled study evaluating D-serine in Parkinson’s disease. The trial is recruiting 100 participants across sites in Norway, with change in MDS-UPDRS Total Score (Parts I–III) as the primary endpoint.

Translational model

The SPARK NS Translational Research Program is modeled on the Stanford SPARK program, which was established to address the “valley of death” in academic drug development, where promising laboratory discoveries often fail to progress due to limited access to industry expertise, regulatory guidance, and milestone-driven funding.

Under this model, academic investigators are paired with volunteer drug development professionals from industry who provide mentorship in areas including medicinal chemistry, pharmacokinetics, toxicology, regulatory strategy, and clinical trial planning. Projects undergo regular milestone-based reviews intended to terminate low-probability programs early and prioritize those with a viable path to clinical testing.

SPARK NS represents a disease-focused adaptation of this framework for autism and Parkinson’s disease. In addition to funding, participating research teams receive ongoing advice from more than 90 industry expert advisors, along with education in drug development and translational research and post-program support to facilitate progression into later-stage development.

Academic connections

Principal investigators funded by SPARK NS are affiliated with institutions including Stanford University, Harvard Medical School, Northwestern University, the University of California San Francisco, Icahn School of Medicine at Mount Sinai, Imperial College London, KU Leuven, and Ulm University.

Intellectual property associated with individual projects is expected to reside with the originating institution or investigator rather than with SPARK NS.